Pfizer Inc. (NYSE:PFE) has finally decided what investors wanted to hear. The world's second-largest pharmaceutical company has given up the idea to split its business, ending years of uncertainty and speculations which had surrounded PFE stock.
The waiting period relating to the Pfizer Inc. (NYSE:PFE) pending acquisition of Medivation, Inc. (NASDAQ:MDVN) has already expired last week as per the amended Hart-Scott-Rodino Antitrust Improvements Act of 1976.
NEW YORK Pfizer Inc (PFE.N), which was considering splitting itself for more than two years, said on Monday it would not do so, prompting shareholders to expect more deals that could bolster its roster of new medicines.
ROCKVILLE, Md.--(BUSINESS WIRE)--OncoImmune, Inc. today announced that it has entered into an exclusive option and license agreement with Pfizer Inc. (NYSE: PFE) for ONC-392, a novel, differentiated preclinical anti-CTLA4 monoclonal antibody in a ...